Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE Inc. has demonstrated robust financial health, with a 23% year-over-year revenue increase, reaching $46.4 million in Q2 2025. The company also achieved a notable improvement in gross margin, increasing approximately 80 basis points year-over-year to 79.8%. Furthermore, the positive momentum is reflected in an upward revision of the 2025 revenue estimate to $196.5 million, bolstered by strong performance in Q2 and enhanced sales productivity.

Bears say

The analysis highlights fundamental concerns regarding SI-BONE Inc.'s stock due to ongoing challenges within the global spine market, which has been experiencing low-single-digit growth attributed to pricing and procedural headwinds. Furthermore, the company faces potential market share erosion in the sacroiliac joint fusion market if payors opt to reimburse competitive products, which could significantly impact its revenue. Finally, SI-BONE's enterprise value to sales growth ratio of 0.19x is considerably lower than the median of 0.34x for its small to mid-cap growth peers, indicating a lack of investor confidence in its growth prospects compared to competitors.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.